About Indapta
Indapta is a company based in Seattle (United States) founded in 2016. Indapta has raised $72.5 million across 3 funding rounds from investors including HHS, RA Capital and Leaps by Bayer. Indapta offers products and services including G-NK Cell Therapy. Indapta operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$72.5 M (USD)
in 3 rounds
-
Latest Funding Round
$22.5 M (USD), Series A
Dec 17, 2024
-
Investors
HHS
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Indapta
Indapta offers a comprehensive portfolio of products and services, including G-NK Cell Therapy.
Allogeneic therapy targeting cancer and autoimmune diseases via NK cells
People of Indapta
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Indapta
Indapta has successfully raised a total of $72.5M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Indapta
Indapta has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RA Capital and Leaps by Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life sciences sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked |
Investor details for Indapta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Indapta
Investment portfolio details for Indapta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Indapta
Detailed financials for Indapta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Indapta Comparisons
Peer comparison for Indapta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Indapta
Indapta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
|
| Locked | Locked | Locked |
CDMO offering drug and biologics development services
|
|
| Locked | Locked | Locked |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| Locked | Locked | Locked |
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
|
| Locked | Locked | Locked |
Drug research, development, testing, and consulting services are provided.
|
|
| Locked | Locked | Locked |
Provides contract research, development, and manufacturing services for biologic drugs.
|
Detailed competitors of Indapta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Indapta
Complete news archive for Indapta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Indapta
Indapta was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Indapta is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Indapta is a funded company, having raised a total of $72.5M across 3 funding rounds to date.
Indapta, established in 2016, excels in providing healthcare solutions, biopharma outsourcing, diversified, and biologics. Limited information available. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide. It continues to evolve, meeting industry challenges with strategic approaches.
Indapta offers G-NK Cell Therapy.
Indapta has 6 investors. Key investors include HHS, RA Capital, Leaps by Bayer, Vertex Ventures HC, and Pontifax Venture Capital.